Noninvasive point-of-care measurement of gastrointestinal permeability

Richard B. Dorshow; J. R. Johnson; Martin P. Debreczeny; I. Rochelle Riley; Jeng-Jong Shieh; Thomas E. Rogers; Carla Hall-Moore; Nurmohammad Shaikh; Phillip I. Tarr

doi:10.1117/12.2507965

7 March 2019 Noninvasive point-of-care measurement of gastrointestinal permeability

Richard B. Dorshow, J. R. Johnson, Martin P. Debreczeny, I. Rochelle Riley, Jeng-Jong Shieh, Thomas E. Rogers, Carla Hall-Moore, Nurmohammad Shaikh, Phillip I. Tarr

Author Affiliations +

Proceedings Volume 10893, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications XI; 1089307 (2019) https://doi.org/10.1117/12.2507965
Event: SPIE BiOS, 2019, San Francisco, California, United States

Abstract

The intestinal mucosal barrier prevents macromolecules and pathogens from entering the circulatory stream in a healthy gut. Tight junctions in this barrier are compromised in many intestinal disorders including inflammatory bowel diseases (such as Crohn’s and ulcerative colitis), celiac disease, graft vs host disease, environmental enteropathy, and enteric dysfunction. Dual sugar absorption tests are a standard method for measuring gastrointestinal integrity in humans. The larger molecular weight sugar, lactulose, is minimally absorbed through a healthy gut. The smaller molecular weight sugar, mannitol or rhamnose, in contrast, is readily absorbed through both a healthy and inflamed gut. Thus, a higher ratio of lactulose to mannitol or rhamnose reflects increased intestinal permeability. However, several issues prevent the widespread use of the dual sugar assay including requirements for lengthy urine collection, transport of specimens under conditions free from contamination and bacterial growth, analysis by sophisticated laboratory equipment, and the associated lengthy turnaround time. In a recent publication, the feasibility of employing a dual fluorescent tracer agent assay to mimic the dual sugar absorption test without the need for specimen collection was reported. This dual fluorophore assay for GI permeability was demonstrated in an indomethacin-induced bowel disease model in rats. However, one of the fluorophores was not entirely biocompatible. Herein is reported a dual fluorophore system that is totally biocompatible, with emphasis on the transdermal detection of the fluorophores, thus enabling the use of the technology for noninvasive point-of-care gastrointestinal permeability determination.

Citation Download Citation

Richard B. Dorshow, J. R. Johnson, Martin P. Debreczeny, I. Rochelle Riley, Jeng-Jong Shieh, Thomas E. Rogers, Carla Hall-Moore, Nurmohammad Shaikh, and Phillip I. Tarr "Noninvasive point-of-care measurement of gastrointestinal permeability ", Proc. SPIE 10893, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications XI, 1089307 (7 March 2019); https://doi.org/10.1117/12.2507965

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available